FDA to Review Dry Powder Inhalation Formulation of Treprostinil
Tyvaso DPI is an investigational drug-device combination therapy consisting of a dry powder formulation of treprostinil.
Pulmonary Arterial Hypertension
Riociguat May Be Useful Alternative to PDE5i Therapy in Pulmonary Arterial Hypertension
Riociguat may be a useful option for patients with pulmonary arterial hypertension in whom phosphodiesterase-5 inhibitor treatment is insufficient.
Examining Changes in PASP After Atrial Defect Closure in Older Patients With Systolic, Diastolic, and Renal Dysfunction
Patients who are older and have systolic, diastolic, and renal dysfunction may benefit from peri-interventional preload reduction therapy before implantation of larger left atrial devices.
Exercise Doppler Echocardiography Found to Consistently Assess Right Heart, Pulmonary Circulation
Exercise Doppler echocardiography may provide consistent assessment of right heart function and pulmonary circulation when conducted at expert centers.
High Hepatic Growth Factor Levels Add Predictive Value to PAH Risk Score
In pulmonary arterial hypertension, high plasma levels of hepatic growth factor are associated with the right heart maladaptive phenotype and are incremental to the REVEAL score for the prediction of patient outcomes.
Inhaled Treprostinil Beneficial in Pulmonary Hypertension
Exercise capacity improved, clinical worsening reduced for patients with pulmonary HTN due to interstitial lung disease.
Implantable Infusion Pump for Treprostinil in Pulmonary Arterial Hypertension Is Safe, Feasible
Patients with pulmonary arterial hypertension (PAH) who were treated with treprostinil using an implantable infusion pump experienced few serious complications.
Noninvasive Combinatorial Model Predicts Pulmonary Hypertension
A combinatorial model was devised to predict pulmonary hypertension using systolic pulmonary artery pressure and forced vital capacity in older adults.
Pulmonary Artery Denervation for the Treatment of PAH
Pulmonary artery denervation has been found to reduce the sympathetic activity of the pulmonary circulation.
Hospitalizations Lower in Patients With Pulmonary Arterial Hypertension Receiving Selexipag or Treprostinil
Researchers sought to determine if selexipag can be associated with lower hospitalization rates through analysis of real-world hospitalization rates of patients taking either selexipag or treprostinil.
- Loading...
Loading...
Next post in Pulmonary Vasculature
Loading... 
Loading...